Longeveron Discusses Latest Stem Cell Findings for Aging Frailty at the International Conference on Frailty & Sarcopenia Research
FEBRUARY 19, 2019
Longeveron LLC, a biopharmaceutical company that develops cellular therapies for aging-related diseases, will discuss the company's latest clinical research of its stem cell treatments for Aging Frailty at the International Conference on Frailty & Sarcopenia Research, to be held February 20-22 at the Eden Roc Hotel on Miami Beach
MIAMI, Feb. 19, 2019 /PRNewswire/ -- Longeveron LLC, a biopharmaceutical company that develops cellular therapies for aging-related diseases, will discuss the company's latest clinical research of its stem cell treatments for Aging Frailty at the International Conference on Frailty & Sarcopenia Research, to be held February 20-22 at the Eden Roc Hotel on Miami Beach.
Longeveron's session, "Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells as a Treatment for Aging-Related Indications," is scheduled for Thursday, February 21 at 11:40 am. The company will discuss the positive results of its Phase I and Phase 2 trials examining the safety and efficacy of its stem cell treatments for Aging Frailty. Trial participants, with an average age of 76, showed marked improvement in physical performance, lung function and reduction of inflammation, all significant biomarkers of Frailty. The company is now recruiting for an expanded Phase 2b Aging Frailty study,
The company will also review the progress of its Phase 1 clinical trial to evaluate the safety and efficacy of its Mesenchymal Stem Cells in patients with Alzheimer's disease, and its Phase 1 and Phase 2 trials to evaluate the safety and efficacy of its stem cells for improving flu vaccine immune response in older patients. Longeveron's MSC product is derived from the bone marrow of young, healthy adult donors.
On Friday, February 22, from 8 to 9 am, Longeveron will also host a breakfast industry symposium, "Trends in Anti-Aging Research Aimed at Extending the Healthspan."
"By 2050, the global population age 60 and over is expected to reach two billion. Aging Frailty is now recognized as a serious geriatric syndrome that leads to other severe serious health conditions, such as heart disease and lung disease. Our research so far has demonstrated that regenerative stem cell therapies hold great potential to improve healthspans – health and quality of life at the later stages of life – and to ameliorate the chronic, debilitating conditions associated with aging," said Geoff Green, Longeveron SVP of Clinical Operations.
Frailty and sarcopenia – the age-related loss of muscle mass – have emerged as serious health concerns worldwide and major reasons for the loss of functional independence among older people. At the conference, Longeveron will join other noted scientists and researchers describing recent progress in understanding frailty and sarcopenia, and developing interventions to prevent or treat these conditions. ICFSR 2019 features five keynote addresses, eight symposia, 13 mini-conferences and 42 additional oral presentations.
About Longeveron LLC
Longeveron (www.longeveron.com) is a regenerative medicine therapy company founded in 2014. Longeveron’s mission is to provide biological solutions for aging-related diseases and life-threatening conditions, and is dedicated to developing safe and effective cell-based therapeutics for unmet medical needs such as Aging Frailty, the Metabolic Syndrome, Alzheimer’s Disease and congenital heart defects
in children (hypoplastic left heart syndrome).
For additional information please contact:
Chief Financial Officer Longeveron, LLC